Results 181 to 190 of about 71,440 (310)

Tobacco and cannabis use in the young ‘Not in Employment, Education or Training’ population: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims NEET (Not in Employment, Education or Training) youth represent a vulnerable population from a public health perspective, facing multiple health challenges, including elevated substance use. Tobacco and cannabis are the most commonly used psychoactive substances among young people, with early initiation associated with long‐
Clara Eyraud, Claire Collin, Philippe Martin, Corinne Alberti, Laëtitia Minary, Agnès Dumas, Enora Le Roux   +6 more
wiley   +1 more source

A phone-based tobacco use cessation program for people living with HIV in Uganda and Zambia: study protocol for a randomized controlled trial. [PDF]

Addict Sci Clin Pract
Wipfli H, Arinaitwe J, Goma F, Atuyambe L, Guwatudde D, Phiri MM, Rutebemberwa E, Wabwire-Mangen F, Zulu R, Zyambo C, Guy K, Kusolo R, Mukupa M, Musasizi E, Tucker JS.   +14 more
europepmc   +1 more source

Barriers and facilitators to detoxification from opioid substitution treatment: A mixed‐methods systematic review

Addiction, EarlyView.
Abstract Background and aims Despite the well‐documented benefits of opioid substitution treatment (OST) in treating opioid dependence (OD), many people diagnosed with OD desire to live a drug‐free life. The transition to abstinence involves detoxification: a gradual dose reduction of OST to zero milligrams.
Amy Bagshaw, Suleyman Shah, India Olchefske, Louise M. Paterson, Mike J. Crawford, Anne Lingford‐Hughes   +5 more
wiley   +1 more source

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Addiction, EarlyView.
Abstract Background and aims Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to ...
Emmert Roberts, Elizabeth Sanderson, Thomas Santo Jr., Matthew Hickman, Michael Farrell, Louisa Degenhardt   +5 more
wiley   +1 more source

Prevalence and risk perceptions of nicotine pouch use: A systematic review of population‐based studies

Addiction, EarlyView.
Abstract Background and Aims Oral nicotine pouches (NPs) are a new class of non‐combustible nicotine products that have gained rapid popularity. Despite rising sales and marketing, evidence of their prevalence and risk perceptions remains limited. This systematic review aimed to synthesize the available global evidence on the prevalence and patterns of
Salma Mahmoodianfard, Spencer Shahen, Javad Heshmati, Emma Bates, Evyanne Quirouette, Terefe Gelibo, Sarah Visintini, Hassan Mir   +7 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Mitigating policy uncertainty: What financial markets reveal about firm‐level lobbying

American Journal of Political Science, EarlyView.
Abstract Elections can lead to substantial policy changes and, thus, are a significant source of risk. Firms can respond to such policy uncertainty by lobbying, but it is hard to quantify whether they do so and, if so, how much lobbying benefits them. We construct a new dataset and leverage investors’ expectations of variability in stock returns in the
Kristy Buzard, Nathan Canen, Sebastian Saiegh   +2 more
wiley   +1 more source

Tobacco Use, Cessation Research [PDF]

, 2020
openaire   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source

Change in self-reported tobacco cessation support practices among HIV providers in Kisumu, Kenya: a pre-post evaluation of a web-based training programme nested within the IN-ToUCH cluster randomised trial. [PDF]

BMJ Public Health
Olando YA, Onyango RM, Bukusi EA, Brown J, Ongeri L, Shade SB, Vijayaraghavan M, Odhiambo FA, Osongo CO, Cohen CR, Magati P, Kwena Z, Rota G, Chatterjee P, Osula CA, Ouner JJ, Bialous SS.   +16 more
europepmc   +1 more source